Patents by Inventor Hidetaka Kaku
Hidetaka Kaku has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8222274Abstract: [Problem] To provide a compound which may be used for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).Type: GrantFiled: February 19, 2007Date of Patent: July 17, 2012Assignee: Astellas Pharma Inc.Inventors: Ryushi Seo, Hidetaka Kaku, Hiroyoshi Yamada, Daisuke Kaga, Shinobu Akuzawa
-
Patent number: 7989634Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.Type: GrantFiled: November 12, 2004Date of Patent: August 2, 2011Assignees: LG Life Sciences Ltd., Yamanouchi Pharmaceutical Co., Ltd.Inventors: Koo Lee, Heui-Sul Park, In-Ae Ahn, Hyun-Ju Yoo, Jong-Yup Kim, Deog-Young Choi, Hyeon-Joo Yim, Kyung-Ha Chung, Dong-Sup Shim, Sang-Kyun Lee, Yutaka Kondoh, Ryoji Hirabayashi, Shugo Honda, Hidetaka Kaku, Jun-ichi Shishikura, Hiroyuki Ito, Takeshi Kurama
-
Patent number: 7985764Abstract: It was found that a compound according to the following formula: or a pharmaceutically acceptable salt thereof, has a strong antagonism for both the 5-HT2B and 5-HT7 receptors. In addition, the compound shows good pharmacological action as compared to antagonists selective for only one of these receptors. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).Type: GrantFiled: February 7, 2007Date of Patent: July 26, 2011Assignee: Astellas Pharma Inc.Inventors: Hidetaka Kaku, Hiroyoshi Yamada, Daisuke Kaga, Ryushi Seo, Shinobu Akuzawa
-
Publication number: 20110009379Abstract: [Problems] A compound, which is useful as an active ingredient for a pharmaceutical composition, for example a pharmaceutical composition for treating constipation-type irritable bowel syndrome, atonic constipation and/or functional gastrointestinal disorder, is provided. [Means for Solution] The present inventors have extensively studied compounds having TRPA1 channel activation activity, and confirmed that an indolinone compound has a TRPA1 channel activation activity, and thus completed the present invention. The indolinone compound of the present invention has a TRPA1 channel activation activity and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating constipation-type irritable bowel syndrome, atonic constipation and/or functional gastrointestinal disorder or the like.Type: ApplicationFiled: March 30, 2009Publication date: January 13, 2011Applicant: ASTELLAS PHARMA INC.Inventors: Hidetaka Kaku, Tomofumi Takuwa, Michihito Kageyama, Katsura Nozawa, Hitoshi Doihara
-
Publication number: 20090062363Abstract: [Problem] To provide a compound which can be used for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that an amide derivative characterized by the possession of a nitrogen-containing bicyclic hetero ring (e.g., an indole or the like), or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).Type: ApplicationFiled: February 7, 2007Publication date: March 5, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Hidetaka Kaku, Hiroyoshi Yamada, Daisuke Kaga, Ryushi Seo, Shinobu Akuzawa
-
Publication number: 20090036421Abstract: [Problem] To provide a compound which may be used for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).Type: ApplicationFiled: February 19, 2007Publication date: February 5, 2009Applicant: ASTELLAS PHARMA INCInventors: Ryushi Seo, Hidetaka Kaku, Hiroyoshi Yamada, Daisuke Kaga, Shinobu Akuzawa
-
Publication number: 20070129346Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.Type: ApplicationFiled: November 12, 2004Publication date: June 7, 2007Applicants: LG Life Sciences Ltd., Yamanouchi Pharmaceutical Co., Ltd.Inventors: Koo Lee, Heui-Sul Park, In-Ae Ahn, Hyun-Ju Yoo, Jong-Yup Kim, Deog-Young Choi, Hyeon-Joo Yim, Kyung-Ha Chung, Dong-Sup Shim, Sang-Kyun Lee, Yutaka Kondoh, Ryoji Hirabayashi, Shugo Honda, Hidetaka Kaku, Jun-ichi Shishikura, Hiroyuki Ito, Takeshi Kurama